The FDA approved Dextenza for intracanalicular use for the treatment of ocular pain after ophthalmic surgery, Ocular Therapeutix announced in a press release.
Dextenza (dexamethasone ophthalmic insert 0.4 mg) is the first FDA-approved intracanalicular insert to deliver dexamethasone to treat postoperative ocular pain for up to 30 days with one treatment.
“We are extremely pleased to announce the approval of Dextenza, coming so soon after our preapproval inspection and approximately 1 month ahead of the PDUFA date,” Antony Mattessich, Ocular Therapeutix president and CEO, said in the
Uncategorized